Analysts see little effect on the bottom lines of biopharma companies, as they stand to stave off tariff pressure and receive ...
The clearance brings an oral form of Novo’s Wegovy to market ahead of Lilly’s rival medication and kicks off the next phase ...
The startup’s filing comes during a broader biotech recovery that’s made some industry watchers optimistic IPOs could rebound ...
The overall leadership outlook was positive in a recent survey but varied between executives in the U.S. and those overseas.
Two pilot programs would tie Medicare costs and rebates in the U.S. to what’s paid in comparable countries. Elsewhere, AstraZeneca reported a setback and an “off the shelf” cell therapy showed promise ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback